Posted in | News | Business

BHP Billliton Completes Acquisition of Anglo Potash

BHP Billiton today announced that it has completed the previously announced acquisition of all the issued and outstanding common shares of Anglo Potash Ltd. ("Anglo Potash") for C$8.15 per share in cash.

This acquisition provides BHP Billiton with 100 per cent control of the Canadian potash Joint Venture development project established between BHP Billiton and Anglo Potash in June 2006.

BHP Billiton also announced that an application to delist Anglo Potash's common shares has been filed with the TSX Venture Exchange and the delisting is expected to be effective within three trading days. An application is expected to be filed shortly to allow Anglo Potash to cease to be a reporting issuer under applicable Canadian provincial securities laws.

BHP Billiton Diamonds and Specialty Products President Graham Kerr said, "I am pleased with the overwhelming support received from shareholders of Anglo Potash for this acquisition, which further enhances BHP Billiton's position in the world’s major potash basin by adding flexibility for future growth".

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BHP. (2019, February 10). BHP Billliton Completes Acquisition of Anglo Potash. AZoM. Retrieved on November 21, 2024 from https://www.azom.com/news.aspx?newsID=12890.

  • MLA

    BHP. "BHP Billliton Completes Acquisition of Anglo Potash". AZoM. 21 November 2024. <https://www.azom.com/news.aspx?newsID=12890>.

  • Chicago

    BHP. "BHP Billliton Completes Acquisition of Anglo Potash". AZoM. https://www.azom.com/news.aspx?newsID=12890. (accessed November 21, 2024).

  • Harvard

    BHP. 2019. BHP Billliton Completes Acquisition of Anglo Potash. AZoM, viewed 21 November 2024, https://www.azom.com/news.aspx?newsID=12890.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.